Last $9.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

ranbaxy labora-unsp gdr regs (RBXZF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/21/14 - $10.50
52 Week Low
02/11/14 - $5.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ranbaxy labora-unsp gdr regs (RBXZF) Related Businessweek News

View More BusinessWeek News

ranbaxy labora-unsp gdr regs (RBXZF) Details

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbaxy Laboratories Limited operates in India, Europe, North America, the Asia Pacific, and Africa. The company was founded in 1961 and is headquartered in New Delhi, India. Ranbaxy Laboratories Limited is a subsidiary of Daiichi Sankyo Company, Ltd.

15,300 Employees
Last Reported Date: 07/1/14
Founded in 1961

ranbaxy labora-unsp gdr regs (RBXZF) Top Compensated Officers

Managing Director, Chief Executive Officer, E...
Total Annual Compensation: 122.7M
Compensation as of Fiscal Year 2014.

ranbaxy labora-unsp gdr regs (RBXZF) Key Developments

Epirus Switzerland GmbH Enters Amendment to License Agreement with Ranbaxy Laboratories Limited

On September 9, 2014, Epirus Switzerland GmbH entered into an amendment to that certain license agreement between the company and Ranbaxy Laboratories Limited, dated as of January 3, 2014. Under the license agreement, the company granted exclusive rights under its intellectual property and regulatory materials to Ranbaxy for the development and commercialization of its BOW015 product in India and certain other countries in Asia and North Africa, as further described in the company's quarterly report for its quarter ended June 30, 2014. The amendment amends the license agreement to revise the royalty tiers for net sales based on final product sale forecasts and supply costs in the territory, and Ranbaxy's obligations with respect to minimum annual sales targets in any given country such that the obligations are subject to a final grant of approval for BOW015 by the applicable regulatory authority for all indications as have been granted for the innovator product in such country. Other than as in the amendment, the license agreement remains in full force and effect following the parties' execution of the amendment.

Ranbaxy Laboratories Announces Management Changes

Ranbaxy Laboratories's global HR head Sandeep Girotra has stepped down while its president of global pharma business, Rajiv Gulati, plans to leave soon. Both Girotra and Gulati have been part of the executive management council, the 10-member apex body that provides functional leadership to the company, people familiar with matter told ET. Besides, Ranbaxy has appointed Alexander Gebauer as its new head of global research and development. Gessner and Gebauer, both German, have been inducted in the executive management council of the firm. Adkisson, a Daiichi veteran, was Ranbaxy's global quality and compliance head. He had joined Ranbaxy in early 2010 when the company was dogged by regulatory setbacks in the United States. Gessner, who replaces him, was Ranbaxy's regional director of quality in charge of Europe, Africa and East Europe. Gebauer was formerly the R&D chief of Merz Pharma and has worked with Sanofi Aventis. He steps into the role of Sudershan Arora, whose post had fallen vacant after he retired as the president of R&D last year. Gulati has been on a long leave for personal reasons and during this period his work has been looked after by Ranjan Chakravarti as additional charge, a person familiar with the matter said. Chakravarti serves as the head of transformation and business consulting and, more importantly, also heads the integration committee that Ranbaxy and Sun have formed to ease the process of merger. Gulati plans to leave by September, the person added.

Ranbaxy Laboratories Ltd., Special/Extraordinary Shareholders Meeting, Sep 19, 2014

Ranbaxy Laboratories Ltd., Special/Extraordinary Shareholders Meeting, Sep 19, 2014., at 11:00 Indian Standard Time. Location: Auditorium of The National Institute of Pharmaceutical Education and Research (NIPER). Agenda: To consider Scheme of Arrangement providing inter-alia merger of the company with Sun Pharmaceutical Industries Limited.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBXZF:US $9.80 USD 0.00

RBXZF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 854.65 INR +2.25
Cadila Healthcare Ltd 1,311 INR +24.95
Richter Gedeon Nyrt 4,062 0.00
Glenmark Pharmaceuticals Ltd 737.05 INR -1.10
Krka dd Novo mesto €65.74 EUR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation RBXZF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RANBAXY LABORA-UNSP GDR REGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at